The field of regenerative medicine is becoming an exciting area in both human and veterinary medicine that may greatly impact our ability to treat patients. Two main tools extensively being investigated are platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) and how they may aid in the treatment of orthopedic diseases. The PRP is plasma with a greater concentration of platelets than that found in whole blood, and rationale for its use arises from the release of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGFβ), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and insulin-like growth factors 1 and 2 (IGF), and other cytokines, including interleukin 8. These molecules are released from the alpha granules when platelets rupture or lyse. This process is also referred to as activation of PRP and it is these growth factors and cytokines that locally induce endogenous bone and soft tissue regeneration. Plateletrich- plasma also offers a significant advantage over other potential cell-based therapies in that it is autologous (i.e. the donor and the patient are the same), and hence, avoiding graft vs. host complications.